Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 9, 2012, Pages 989-997

  Walker, Naomi F ^a,b,c   Clark, Simon O ^d   Oni, Tolu ^a,c   Andreu, Nuria ^a   Tezera, Liku ^a   Singh, Shivani ^a   Saraiva, Luísa ^a   Pedersen, Bernadette ^a   Kelly, Dominic L ^d   Tree, Julia A ^d   D'Armiento, Jeanine M ^e   Meintjes, Graeme ^a,c   Mauri, Francesco A ^a   Williams, Ann ^d   Wilkinson, Robert J ^a,b,c,f   Friedland, Jon S ^a,b   Elkington, Paul T ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e Howard Hughes Medical Institute   (United States)

^f NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Immunopathology; Lung; Mycobacteria; Protease inhibitors

Indexed keywords

ALPHA INTERFERON; DOXYCYCLINE; EOTAXIN; GAMMA INTERFERON; GELATINASE A; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; RANTES; SCATTER FACTOR; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; EXPERIMENTAL PIG; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MALE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPUTUM; TISSUE INJURY; TUBERCULOSIS;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; CD4 LYMPHOCYTE COUNT; CYTOKINES; DOXYCYCLINE; GUINEA PIGS; HIV INFECTIONS; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84860621068     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201110-1769OC     Document Type: Article

References (49)

1. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010;328:856-861.
2. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ 2002;325:1282-1286. (Pubitemid 35430589)
3. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, et al. Epidemiology of anti-tuberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet 2009;373:1861-1873.
4. Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Barnashov A, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010;182:426-432.
5. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010;181:80-86.
6. Yew WW, Sotgiu G, Migliori GB. Update in tuberculosis and nontuberculous mycobacterial disease 2010.AmJ Respir Crit Care Med 2011;184:180-185.
7. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009;27:393-422.
8. Anandaiah A, Dheda K, Keane J, Koziel H, Moore DA, Patel NR. Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection. Am J Respir Crit Care Med 2011; 183:987-997.
9. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362:887-899. (Pubitemid 37130100)
10. Schwander S, Dheda K. Human lung immunity against mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med 2011;183:696-707.
11. Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 2011;24:351-376.
12. Elkington PT, D'Armiento JM, Friedland JS. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med 2011;3:71ps76.
13. Elkington PT, Nuttall RK, Boyle JJ, O'Kane CM, Horncastle DE, Edwards DR, Friedland JS. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am J Respir Crit Care Med 2005;172:1596-1604. (Pubitemid 43076552)
14. Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, Walker NF, Saraiva L, Pedersen B, Mauri F, Lipman M, et al. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest 2011;121:1827-1833.
15. Rand L, Green JA, Saraiva L, Friedland JS, Elkington PT. Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPKdependent, p-aminosalicylic acid-sensitive signaling cascade. J Immunol 2009;182:5865-5872.
16. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010;327:466-469.
17. Salgame P. MMPs in tuberculosis: granuloma creators and tissue destroyers. J Clin Invest 2011;121:1686-1688.
18. Brinckerhoff CE, Matrisian LM.Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-214.
19. Golub LM, McNamara TF, Ryan ME, Kohut B, Blieden T, Payonk G, Sipos T, Baron HJ. Adjunctive treatment with sub-antimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J Clin Periodontol 2001;28:146-156. (Pubitemid 33761359)
20. Elkington PT, Green JA, Friedland JS. Filter sterilization of highly infectious samples to prevent false negative analysis of matrix metalloproteinase activity. J Immunol Methods 2006;309:115-119. (Pubitemid 43190807)
21. Lawson L, Yassin MA, Thacher TD, Olatunji OO, Lawson JO, Akingbogun TI, Bello CS, Cuevas LE, Davies PD. Clinical presentation of adults with pulmonary tuberculosis with and without HIV infection in Nigeria. Scand J Infect Dis 2008;40:30-35.
22. Elkington PT, Emerson JE, Lopez-Pascua LD, O'Kane CM, Horncastle DE, Boyle JJ, Friedland JS. Mycobacterium tuberculosis up-regulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J Immunol 2005;175:5333-5340. (Pubitemid 41456419)
23. Chambers MA, Williams A, Gavier-Widen D, Whelan A, Hughes C, Hall G, Lever MS, Marsh PD, Hewinson RG. A guinea pig model of low-dose Mycobacterium bovis aerogenic infection. Vet Microbiol 2001;80:213-226. (Pubitemid 32406107)
24. Mavhu W, Dauya E, Bandason T, Munyati S, Cowan FM, Hart G, Corbett EL, Chikovore J. Chronic cough and its association with TB-HIV coinfection: factors affecting help-seeking behaviour in Harare, Zimbabwe. Trop Med Int Health 2010;15:574-579.
25. Sang QX, Jin Y, Newcomer RG, Monroe SC, Fang X, Hurst DR, Lee S, Cao Q, Schwartz MA. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 2006;6:289-316.
26. Elkington PT, Green JA, Emerson JE, Lopez-Pascua LD, Boyle JJ, O'Kane CM, Friedland JS. Synergistic up-regulation of epithelial cell matrix metalloproteinase-9 secretion in tuberculosis. Am J Respir Cell Mol Biol 2007;37:431-437. (Pubitemid 47502718)
27. Andreu N, Fletcher T, Krishnan N, Wiles S, Robertson BD. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother 2012;67:404-414.
28. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617-629. (Pubitemid 39025047)
29. Ganachari M, Ruiz-Morales JA, Gomez de la Torre Pretell JC, Dinh J, Granados J, Flores-Villanueva PO. Joint effect of MCP-1 genotype GG and MMP-1 genotype 2G/2G increases the likelihood of developing pulmonary tuberculosis in BCG-vaccinated individuals. PLoS ONE 2010;5:e8881.
30. Gapski R, Hasturk H, Van Dyke TE, Oringer RJ, Wang S, Braun TM, Giannobile WV. Systemic MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled clinical trial. J Clin Periodontol 2009;36:149-156.
31. Alvarez JI, Krishnamurthy J, Teale JM. Doxycycline treatment decreases morbidity and mortality of murine neurocysticercosis: evidence for reduction of apoptosis and matrix metalloproteinase activity. Am J Pathol 2009;175:685-695.
32. Meli DN, Coimbra RS, Erhart DG, Loquet G, Bellac CL, Tauber MG, Neumann U, Leib SL. Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect Immun 2006;74:3890-3896. (Pubitemid 43993320)
33. Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 2003;47:3630-3633. (Pubitemid 37345735)
34. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009;119:2209-2216.
35. Green JA, Elkington PT, Pennington CJ, Roncaroli F, Dholakia S, Moores RC, Bullen A, Porter JC, Agranoff D, Edwards DR, et al.Mycobacterium tuberculosis upregulates microglial matrix metalloproteinase-1 and -3 expression and secretion via NF-kB and activator protein-1-dependent monocyte networks. J Immunol 2010;184:6492-6503.
36. Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis 2005;192:1201-1209.
37. Izzo AA, Izzo LS, Kasimos J, Majka S. A matrix metalloproteinase inhibitor promotes granuloma formation during the early phase of Mycobacterium tuberculosis pulmonary infection. Tuberculosis (Edinb) 2004;84:387-396. (Pubitemid 39451905)
38. Hernandez-Pando R, Orozco H, Arriaga K, Pavon L, Rook G. Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice. Int J Exp Pathol 2000;81:199-209. (Pubitemid 30485819)
39. North RJ, Jung YJ. Immunity to tuberculosis. Annu Rev Immunol 2004; 22:599-623. (Pubitemid 38680435)
40. Balbin M, Fueyo A, Knauper V, Lopez JM, Alvarez J, Sanchez LM, Quesada V, Bordallo J, Murphy G, Lopez-Otin C. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 2001;276:10253-10262.
41. Helke KL, Mankowski JL, Manabe YC. Animal models of cavitation in pulmonary tuberculosis. Tuberculosis (Edinb) 2006;86:337-348. (Pubitemid 44209336)
42. Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, Visser A, Wang W, Hsu FF, Wiehart U, et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2010;2:258-274.
43. Mehra S, Pahar B, Dutta NK, Conerly CN, Philippi-Falkenstein K, Alvarez X, Kaushal D. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS ONE 2010; 5:e12266.
44. Nedeltchev GG, Raghunand TR, Jassal MS, Lun S, Cheng QJ, Bishai WR. Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect Immun 2009;77:598-603.
45. Heifets LB. Antimycobacterial drugs. Semin Respir Infect 1994;9:84-103. (Pubitemid 24286907)
46. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997;41:1004-1009. (Pubitemid 27194176)
47. Lougheed KE, Taylor DL, Osborne SA, Bryans JS, Buxton RS. New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb) 2009;89:364-370.
48. Balabanova Y, Ruddy M, Hubb J, Yates M, Malomanova N, Fedorin I, Drobniewski F. Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis 2005;24: 136-139. (Pubitemid 40487382)
49. MacArthur CG, Johnson AJ, Chadwick MV, Wingfield HJ. The absorption and sputum penetration of doxycycline. J Antimicrob Chemother 1978;4:509-514. (Pubitemid 9053775)